# US 2019/0169692 A1 · STK32C Gene Relevant to Breast Cancer and Use Thereof > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2019/0169692 A1 - Document ID: US20190169692A1 - Status: Published application - Kind: A1 - Application number: 15/757,696 - Filed: 2016-08-19 - Published: 2019-06-06 - Earliest claimed: 2015-09-07 - Assignees: Dongguk University Industry-Academy Cooperation Foundation - Applicants: Dongguk University Industry-Academy Cooperation Foundation - Inventors: Chang-Hoon Lee - Web page: https://patentgrep.com/patent/US20190169692A1 ## CPC - C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575) - A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy - C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)} - C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)} - C12Y 207/11001: Non-specific serine/threonine protein kinase (2.7.11.1), i.e. casein kinase or checkpoint kinase - G01N 33/50: Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing (measuring or testing processes involving enzymes or microorganisms, compositions or test papers therefor; processes for forming such compositions, condition responsive control in microbiological or enzymological processes C12Q) - G01N 33/575: for cancer - G01N 33/57515: of the breast - A01K 2227/105: Murine - A01K 2267/0331: Animal model for proliferative diseases - C12N 2310/14: interfering nucleic acids [NA] - C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism - C12Q 2600/136: Screening for pharmacological compounds - C12Q 2600/158: Expression markers - G01N 2333/9121: with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases - C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) - C12Y: ENZYMES - G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q) - A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS ## Abstract The present invention relates to the serine threonine kinase 32C (STK32C) gene relevant to breast cancer and a use thereof, and particularly, to a composition for the diagnosis, prevention, or treatment of breast cancer using the STK32C gene. In the present invention, changes in breast cancer cells according to STK32C gene expression differences were identified, and a breast cancer inhibitory effect according to the inhibition of expression of the STK32C gene and YB-1, which is a substrate protein, were newly verified, and thus target therapies are expected in treatment of breast cancer through more fundamental approaches. ## Claims ### Claim at position 1 1-6. (canceled) ### Claim 7 A method of screening a breast cancer therapeutic material, the method comprising the following processes: a) treating serine threonine kinase 32C (STK32C)-expressing cells with a test material; b) measuring an expression or activity degree of STK32C in the cells; and c) selecting a test material that inhibits expression or activity of STK32C when compared to a control not treated with the test material, as a breast cancer therapeutic material. ### Claim 8 (depends on 7) The method of claim 7, wherein the STK32C-expressing cells are selected from the group consisting of MCF-10A, MCF-7, MDA-MB-231, and SK-BR-3 breast cancer cells. ### Claim 9 (depends on 7) The method of claim 7, wherein the measuring of the expression or activity degree of STK32C is performed by measuring a phosphorylation degree of YB-1 by STK32C. ### Claim 10 A method of diagnosing a breast cancer, the method comprising the following processes: a) measuring an expression or activity degree of serine threonine kinase 32C (STK32C) in a subject-derived biological sample using an agent that measures an expression or activity level of STK32C; and b) diagnosing a case in which the measured expression or activity degree of STK32C is higher than that of a normal control, as having breast cancer. ### Claim 11 A method of treating breast cancer, the method comprising administering an expression or activity inhibitor of serine threonine kinase 32C (STK32C) to a subject in need. ### Claim 12 (canceled) ### Claim 13 (depends on 10) The method of claim 10, wherein the agent that measures an expression or activity level of STK32C comprises at least one selected from the group consisting of a primer, a probe, a protein, and an antibody that specifically bind to STK32C. ### Claim 14 (depends on 11) The method of claim 11, wherein the expression inhibitor of STK32C comprises at least one selected from the group consisting of an antisense oligonucleotide, siRNA, shRNA, microRNA, and a ribozyme that specifically bind to STK32C. ### Claim 15 (depends on 11) The method of claim 11, wherein the activity inhibitor of STK32C comprises at least one selected from the group consisting of a compound, a peptide, an aptamer, a protein, and an antibody that specifically bind to STK32C. ### Claim 16 (depends on 11) The method of claim 11, wherein the expression or activity inhibitor of STK32C inhibits the phosphorylation of YB-1.